Compare PRGO & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | HROW |
|---|---|---|
| Founded | 1887 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2013 | N/A |
| Metric | PRGO | HROW |
|---|---|---|
| Price | $12.27 | $40.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $19.33 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.2M | 443.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $1.02 | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.23 | $21.18 |
| 52 Week High | $28.44 | $54.98 |
| Indicator | PRGO | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 53.84 |
| Support Level | $12.17 | $36.75 |
| Resistance Level | $15.08 | $41.67 |
| Average True Range (ATR) | 0.47 | 1.67 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 76.52 | 54.63 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.